Integrated BioTherapeutic Vaccines, a spin-off of Integrated BioTheapeutics changes its name to AbVacc Inc.

On January 3, 2024 Integrated BioTherapeutic Vaccines reported the company changes its name to AbVacc Inc. (Press release, Integrated Biotherapeutics Vaccines, JAN 3, 2023, View Source [SID1234644418]). The mission of AbVacc is to utilize structure-based design for development of next generation vaccines and immunotherapeutics for treatment of infectious and inflammatory diseases. Building upon 15 years of research under the parent company Integrated BioTherapeutics, AbVacc now has a vibrant pipeline of monoclonal antibodies and engineered vaccines in advanced preclinical with several candidate entering the clinical stage in the next few years. To accomplish its ambitious goals, AbVacc has focused on a public-private funding strategy and partnered with various Government funding agencies, primarily National Institute of Allergy and Infectious Diseases (NIAID) and CARB-X as well as private funding sources such as Novo Holdings Repair Impact Fund. Further strategic partnerships include EliteImmune Corp., Scripps Research Institute, La Jolla Institute for Immunology, ViroVax, LLC, University of Texas Medical Branch, Johns Hopkins University, University of Rochester, University of Maryland, and Washington University.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AbVacc operations will remain at 4 research Court, Suite 310, Rockville, MD.